Tech Company Financing Transactions
Ocular Therapeutix Funding Round
Ocular Therapeutix closed a $37.5 million venture capital round on 3/19/2019. Investors included private investors.
Transaction Overview
Company Name
Announced On
3/19/2019
Transaction Type
Debt
Amount
$37,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 1 investor participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
24 Crosby Dr.
Bedford, MA 01730
USA
Bedford, MA 01730
USA
Phone
Website
Email Address
Overview
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a company focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology and ophthalmic surgery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Antony Mattessich
Chief Financial Officer
Donald Notman
Chief Medical Officer
Michael Goldstein
Chief Scientific Officer
Peter Jarrett
VP - General Counsel
Jonathan Sparks
VP - Marketing
Scott Corning
VP - Product Management
Art Driscoll
Browse more venture capital transactions:
Prev: 3/19/2019: Imara Inc. venture capital transaction
Next: 3/19/2019: Danimer Scientific venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs